| Patent application number | Description | Published |
|---|
| 20080200532 | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them - Provided are polymorphic forms of fluvastatin sodium and processes for their preparation. | 08-21-2008 |
| 20080214566 | Amorphous ziprasidone mesylate - Provided is amorphous form of ziprasidone mesylate and process for its preparation. Also provided is a process for preparing ziprasidone mesylate dihydrate needle crystals. | 09-04-2008 |
| 20080214650 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms - The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin. | 09-04-2008 |
| 20080234504 | Processes for preparation of 9-haloacetamidominocyclines - The present invention provides substantially pure intermediates, 9-haloacetomidominocyclines, and process of preparing them that are useful for the preparation of glycylcyclines, specifically Tigecycline. | 09-25-2008 |
| 20080287550 | Sertraline hydrochloride form II and methods for the preparation thereof - The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed. | 11-20-2008 |
| 20080300409 | Crystalline clopidogrel hydrobromide and processes for preparation thereof - Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation. | 12-04-2008 |
| 20080306268 | Crystalline clopidogrel hydrobromide and processes for preparation thereof - Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation. | 12-11-2008 |
| 20080312471 | Polymorphs of atomoxetine hydrochloride - The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder. | 12-18-2008 |
| 20080319191 | Crystalline form IV of linezolid - The present invention provides a novel crystalline form of linezolid referred to herein as Form IV as well as methods for the preparation and use of Form IV. The present invention provides pharmaceutical compositions that comprise therapeutically effective amounts of Form IV that can be used to treat patients suffering from gram-positive bacterial infections. Various processes for making crystalline linezolid Form IV are disclosed. | 12-25-2008 |
| 20090054486 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE - Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI. | 02-26-2009 |
| 20090118297 | POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF - Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof. | 05-07-2009 |
| 20090118518 | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them - Provided are crystalline forms of fluvastatin sodium and processes for their preparation. | 05-07-2009 |
| 20090124642 | Crystalline forms of Erlotinib HCI and formulations thereof - The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof. | 05-14-2009 |
| 20090137821 | Method of making dorzolamide hydrochloride - Processes for the preparation of dorzolamide hydrochloride and an intermediate of Formula IV, | 05-28-2009 |
| 20090143459 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - The present invention provides novel forms of atorvastatin designated Forms VI, VII, VIII, IX, IXa, X, XI, XII, XIV, XVI and XVII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin. | 06-04-2009 |
| 20090156813 | Methods of preparing aripiprazole crystalline forms - The invention encompasses aripiprazole crystalline forms, methods of preparing the same, and pharmaceutical compositions having aripiprazole crystalline forms. | 06-18-2009 |
| 20090187022 | Crystalline clopidogrel hydrobromide and processes for preparation thereof - Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation. | 07-23-2009 |
| 20090209611 | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them - Provided are crystalline forms of fluvastatin sodium and processes for their preparation. | 08-20-2009 |
| 20090264438 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha - Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described. | 10-22-2009 |
| 20090275653 | POLYMORPHIC FORMS OF LADOSTIGIL TARTRATE - The invention provides for solid state chemistry of ladostigil tartrate, particularly polymorphic forms of ladostigil tartrate, and processes for the preparation thereof. | 11-05-2009 |
| 20100004449 | CRYSTALLINE FORMS OF ERLOTINIB BASE AND ERLOTINIB HCL - The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). | 01-07-2010 |
| 20100076225 | Polymorphs of atomoxetine hydrochloride - The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder. | 03-25-2010 |
| 20110112316 | TIGECYCLINE CRYSTALLINE FORMS AND PROCESSES FOR PREPARATION THEREOF - The present invention relates to solid crystalline Tigecycline, and crystalline forms thereof. | 05-12-2011 |
